Outlook Therapeutics, Inc. (OTLK)
0.6405
-0.03
(-3.90%)
USD |
NASDAQ |
Sep 08, 16:00
0.6447
0.00 (0.00%)
Pre-Market: 08:37
Outlook Therapeutics Shareholders Equity (Quarterly) : -10.39M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.39M |
| March 31, 2026 | -28.99M |
| December 31, 2025 | -38.55M |
| June 30, 2025 | -37.19M |
| March 31, 2025 | -32.46M |
| December 31, 2024 | -50.29M |
| September 30, 2024 | -73.08M |
| June 30, 2024 | -83.67M |
| March 31, 2024 | -134.24M |
| December 31, 2023 | -24.34M |
| September 30, 2023 | -14.44M |
| June 30, 2023 | -5.503M |
| March 31, 2023 | 10.49M |
| December 31, 2022 | 15.76M |
| September 30, 2022 | 8.737M |
| June 30, 2022 | 20.08M |
| March 31, 2022 | 35.96M |
| December 31, 2021 | 48.82M |
| September 30, 2021 | 4.607M |
| June 30, 2021 | 12.75M |
| March 31, 2021 | 20.65M |
| Date | Value |
|---|---|
| December 31, 2020 | -10.48M |
| September 30, 2020 | 2.826M |
| June 30, 2020 | 10.97M |
| March 31, 2020 | -20.52M |
| December 31, 2019 | -25.41M |
| September 30, 2019 | -10.77M |
| June 30, 2019 | -1.358M |
| March 31, 2019 | -23.05M |
| December 31, 2018 | -21.47M |
| September 30, 2018 | -20.81M |
| June 30, 2018 | -9.265M |
| March 31, 2018 | -15.27M |
| December 31, 2017 | -7.898M |
| September 30, 2017 | -30.73M |
| June 30, 2017 | -28.94M |
| March 31, 2017 | -26.85M |
| December 31, 2016 | -21.83M |
| September 30, 2016 | -5.200M |
| June 30, 2016 | 1.563M |
| March 31, 2016 | -20.47M |
| December 31, 2015 | -30.91M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Valion Bio, Inc. | 11.88M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 26.18M |
| Total Liabilities (Quarterly) | 36.58M |
| Debt to Equity Ratio | -1.774 |
| Current Ratio | 0.8078 |
| Net Debt Paydown Yield | 0.85% |